Who's Attending in 2024?

Cell and Gene Therapy Pricing, Policy and Reimbursement
Cell and Gene Therapy Pricing, Policy and Reimbursement
Cell and Gene Therapy Pricing, Policy and Reimbursement
Cell and Gene Therapy Pricing, Policy and Reimbursement

Welcome to the Inaugural Cell & Gene Therapy Pricing & Reimbursement Summit!

Cell and gene therapies are reshaping the landscape, offering not just hope but tangible solutions, from curative treatments to sustained remission rates. However, with these groundbreaking advancements come significant challenges in ensuring equitable access and navigating complex coverage and payment structures. 

Our summit brings together leaders from biotech, pharma, healthcare providers, payers, and government agencies to tackle these pressing issues head-on. As we witness landmark approvals like Casgevy by Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia by bluebird bio, the potential for transformative treatments is palpable.  

Join us this June as we dissect the impacts of recent groundbreaking legislative measures, optimize patient access and drive the successful commercial launch of cell and gene therapies. 

Together we can shape the future of healthcare. 

Cell & Gene Therapy Pricing & Reimbursement

The World-Class Speaker Faculty Includes:

2024 Attendees Include:

Cell and Gene Therapy Pricing, Policy and Reimbursement

Our 2024 Partners Include:

What our speakers have to say:

“Cell and gene therapies are relatively new. The impact of these much-needed therapies within an environment that is changing and evolving, especially post-pandemic, is still being discussed and understood, not only from development, regulatory and patient perspectives but also within the payer and market access landscape. These are interesting and innovative times; I am excited to be a part of moving this conversation forward.”

Manpreet Sidhu, Executive Director, Global Health Economics, Outcomes Research and Epidemiology, Ultragenyx